Previous treatment/Course of disease:

In 2001, Biopsy: confirmation of malignancy, Gleason score 5 (2+3) (no report

submitted)

In 2001, 2x Hypethermia as well as diverse alternative treatments

2018-2021, Initiation of anti-androgen, Bicalutamide (initially 50 mg then 150 mg)

2021 Gradual PSA despite Bicalutamide

05/2022, Ga68-PSMA PET/CT (Wiesbaden, Germany): highly PSMA expressing prostatic malignancy with SV invasion, and ECE with at least contact to the anterior rectal wall. Highly PSMA positive pelvic and retroperitoneal LNs, supradiaphragmatic LNs, and multiple bone lesions (Th3, Th12, 7th rib, L5)

05/2022 MRI Pelvis: Prostate volume 43cc. PI-RADS V lesion within the posterior PZ extending just above the apex of the prostate.

11/2022 ADT initiation with Goserelin 10.8 mg (GOC)

12/2022 SBRT of the T3 vertebra TD 30Gy (3Gy x 10)

12/2022 Patient already purchased Enzalutamide and initiated treatment.

12/2022 Pending PET/CT on 20/12